CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Atrium Innovations Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Atrium Innovations Inc.
Place Alexis-Nihon - Tour 2 - 24e étage
3500 boulevard de Maisonneuve Ouest, bureau 2405
Phone: 514-205-6240p:514-205-6240 Westmount, QC  H3Z 3C1  Canada Fax: 418-652-0151f:418-652-0151
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Atrium Innovations Inc. (Atrium) is a Canada-based company engaged in the development, manufacturing, and commercialization of dietary supplements endorsed by health professionals. The Company owns more than 16 brands of products which are distributed mainly in the healthcare practitioner and health food and specialized store channels in more than 35 countries, with a primary focus in North America and Europe. The Company manufactures and markets more than 2,000 health and nutrition finished products. The products are generated primarily from natural sources and include vitamins, minerals and specialized products such as enzymes, probiotics and omega-3. In October 2013, the Company announced that it has acquired 70% interest of Mucos Pharma CZ s.r.o. In February 2014, Atrium Innovations Inc announced the completion of the acquisition of Atrium by corporations backed by the Permirafunds.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
---YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
--Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
5499 Miscellaneous food stores

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board PierreLaurin 51 1/1/2000
President, Chief Executive Officer, Director PierreFitzgibbon 8/1/2007 8/1/2007
Chief Financial Officer, Vice President MarioParadis 4/1/2008 4/1/2008
9 additional Officers and Directors records available in full report.

Business Names
Business Name
AquaCap Pharmaceutical, Inc.
ATB
Atrium Biotechnologies Inc.
9 additional Business Names available in full report.

General Information
Number of Employees: 1,100 (As of 2/27/2013)
Outstanding Shares: 31,299,261 (As of 9/30/2013)
Stock Exchange: TSE
Fax Number: 418-652-0151
Email Address: info@atrium-innovations.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 14, 2024